Biotech

All Articles

Cullinan, after $25M offer, return bispecific to Harbour

.Cullinan Therapeutics was blown away enough with Harbour BioMed's bispecific immune reactor that it...

A closer examine Tough Biotech's Ferocious 15

.In this full week's incident of "The Leading Line," our experts are actually diving in to Ferocious...

Lilly experiences stage 2 breakdown of tau-targeting med

.The confetti is actually still flying from Eli Lilly's event commemorating the approval of Alzheime...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of substantial leadership hirings, shootings as ...

Lykos will inquire FDA to reassess its choice observing rejection of MDMA therapy for post-traumatic stress disorder

.Adhering to an inadequate revealing for Lykos Rehabs' MDMA candidate for post-traumatic stress diso...

AN 2 one-halfs census, ceases period 3 trial after records disappoint

.AN2 Therapeutics is actually reviewing its business in feedback to lackluster midphase information,...

Merck pays $700M for bispecific, snooping autoimmune opening and chance to test Amgen in cancer cells

.Merck &amp Co. is paying out $700 million upfront to challenge Amgen in a blood cancer cells market...

Gilead pays J&ampJ $320M to exit licensing deal for seladelpar

.Along With Gilead Sciences on the verge of an FDA decision for its own liver disease drug seladelpa...

' All hands on deck' at Lilly as peers target weight problems market

.CEO David Ricks can see the business establishing camping tents at basecamp behind Eli Lilly in a t...

Entero laying off personnel, vacating office and pausing R&ampD

.Bed Liquidators has actually turned Entero Therapeutics white as a slab. The lender bought Entero t...